-
Innovation Ranking
NewInnovation Ranking – Revolution Medicines Inc
Revolution Medicines Inc (Revolution Medicines) is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for...
-
Innovation Ranking
NewInnovation Ranking – Editas Medicine Inc
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics,...
-
Innovation Ranking
NewInnovation Ranking – Homology Medicines Inc
Homology Medicines Inc (Homology) is a genetic medicines company that discovers and develops gene therapies to treat genetic disorders. The company is investigating pipeline programs HMI-102, a gene therapy for the treatment of phenylketonuria (PKU); and HMI-202, an investigational gene therapy targeting metachromatic leukodystrophy. It is also evaluating HMI-103, an investigational gene editing program for the treatment of pediatric phenylketonuria, and HMI-203, an investigational gene therapy for the treatment of Hunter syndrome. Homology gene-editing technology is used in DNA repairs,...
-
Innovation Ranking
NewInnovation Ranking – Blueprint Medicines Corp
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is precision therapy company that inventing medicines for people with cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. It also offer GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors...
-
Innovation Ranking
NewInnovation Ranking – Praxis Precision Medicines Inc
Praxis Precision Medicines Inc (Praxis) is a clinical-stage biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050 and PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders. Praxis provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis is headquartered in Cambridge, Massachusetts, the US.
-
Innovation Ranking
NewInnovation Ranking – Huadong Medicine Co Ltd
Huadong Medicine Co Ltd (Huadong Medicine) is a producer and supplier of pharmaceutical products. The company’s product range includes capsules to treat nephropathy, respiratory and immune system diseases; and granules. It offers immunosuppressive and gastrointestinal agents, endocrine, digestive system, antineoplastic, cardiovascular, and antibiotic drugs. The company also manufactures cosmetology and medical equipment. It also involves in handling research and development across various areas including diabetes, oncology, autoimmune field, and others. Huadong Medicine is headquartered in Hangzhou, Zhejiang, China.
-
Innovation Ranking
NewInnovation Ranking – Zhejiang Medicine Co Ltd
Zhejiang Medicine Co Ltd (Zhejiang Medicine) develops, manufactures, and commercializes biological drugs, pharmaceutical intermediates, and bio-pesticides. The company's product portfolio consists of animal nutrition, active pharmaceutical ingredients (APls) and intermediates; antibiotics and human nutrition products including vitamin E, natural vitamin E, vitamin A, vitamin D3 and other pharmaceutical preparations. The company provides its products in large and small volume injections, freeze dried powder injections, tablets, hard and soft capsules, pills and oral solutions. It has two research and development centers,...
-
Innovation Ranking
NewInnovation Ranking – Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its...
-
Product Insights
NewNet Present Value Model: Revolution Medicines Inc’s RMC-6291
Empower your strategies with our Net Present Value Model: Revolution Medicines Inc's RMC-6291 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Everest Medicines Ltd’s SPR-206
Empower your strategies with our Net Present Value Model: Everest Medicines Ltd's SPR-206 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.